cliffwatch

ticagrelor · Astrazeneca · NDA 022433

Brilinta

Earliest generic entry, as listed · earliest of 2 marketed strengths
27 Jul 2036

Blocked by patent: US 10300065.

Listed patents · 5 unexpired

PatentClaimsExpires
US 10300065—27 Jul 2036
US 10300065use U-254227 Jan 2036
US 10300065use U-254127 Jan 2036
US 8425934—17 Oct 2030
US 8425934product17 Apr 2030

Exclusivities · 0 unexpired

No unexpired exclusivities listed.

Paragraph IV certifications · 0

No Paragraph IV certification listed by FDA for this drug.

The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.

Event history

  • 25 Oct 2026Generic approved · 022433-001
  • 25 Oct 2026Generic approved · 022433-001
  • 25 Oct 2026Generic approved · 022433-001
  • 25 Oct 2026Generic approved · 022433-001
  • 25 Oct 2026Generic approved · 022433-001
  • 25 Oct 2026Generic approved · 022433-001
  • 25 Oct 2026Generic approved · 022433-001
  • 25 Oct 2026Generic approved · 022433-001
  • 25 Oct 2026Generic approved · 022433-001
  • 25 Oct 2026Generic approved · 022433-001
  • 25 Oct 2026Generic approved · 022433-001
  • 25 Oct 2026Generic approved · 022433-001
  • 25 Oct 2026Generic approved · 022433-001
  • 25 Oct 2026Generic approved · 022433-001
  • 25 Oct 2026Generic approved · 022433-001

Products covered · 2

NDA · productFormStrengthListed expiry
022433 · 001 · RLDtablet, oral90MG27 Jul 2036
022433 · 002 · RLDtablet, oral60MG27 Jul 2036